Last Updated: November 8, 2026

Patent: 10,835,689

Summary for Patent: 10,835,689

Title:	Methods for inhibiting heterotopic ossification
Abstract:	Methods of protecting muscle tissue from heterotopic ossification employ targeted deliveries of a neuromuscular inhibitor. A method of protecting muscle tissue from heterotopic ossification includes identifying a volume of muscle tissue that is susceptible to heterotopic ossification. A first aliquot of a therapeutic dose of a neuromuscular inhibitor is delivered at a first delivery site within the volume of muscle tissue. A second aliquot of the therapeutic dose is delivered at a second delivery site within the volume of muscle tissue. The first and second delivery sites are separated by a distance to distribute the therapeutic dose within the targeted volume of muscle tissue.
Inventor(s):	Ausk Brandon J., Bain Steven, Gross Ted S.
Assignee:	UNIVERSITY OF WASHINGTON
Application Number:	US15634927
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	United States Patent 10,835,689 Claims and US Patent Landscape: What the Patent Covers, Where It’s Vulnerable, and Who Holds the Surrounding IP Executive summary US Patent 10,835,689 is a US utility patent that (based on the claim text you did not provide) cannot be fully and accurately claim-analyzed or mapped to its enforceable scope, likely design-arounds, or adjacency landscape without the actual claim language. Without the complete set of claims (and their dependent claim structure), it is not possible to determine (i) the operative claim limitations, (ii) which claim terms control infringement analysis, (iii) which limitations likely read on common prior art and obviousness combinations, or (iv) whether the estate is plausibly attackable via anticipation/obviousness, indefiniteness, or written description and enablement. No further patent landscape analysis for US 10,835,689 is provided below because the claim set is missing. More… ↓ ⤷ Start Trial

Details for Patent 10,835,689

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	December 8, 2000	⤷ Start Trial	2037-06-27
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Summary for Patent: 10,835,689

Executive summary

Make Better Decisions: Try a trial or see plans & pricing